Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma-Reference-Cited by-同舟云学术

Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma

Published:2018-04-11 Issue:5 Volume:10 Page:
ISSN:1757-4676
Container-title:EMBO Molecular Medicine
language:en
Short-container-title:EMBO Mol Med

Author:

Echevarría‐Vargas Ileabett M¹,Reyes‐Uribe Patricia I¹,Guterres Adam N¹,Yin Xiangfan¹,Kossenkov Andrew V¹,Liu Qin¹,Zhang Gao¹,Krepler Clemens¹,Cheng Chaoran²,Wei Zhi²,Somasundaram Rajasekharan¹,Karakousis Giorgos³⁴,Xu Wei³,Morrissette Jennifer JD⁵⁶,Lu Yiling⁷,Mills Gordon B⁷,Sullivan Ryan J⁸,Benchun Miao⁸,Frederick Dennie T⁸,Boland Genevieve⁹,Flaherty Keith T⁸,Weeraratna Ashani T¹⁰¹¹,Herlyn Meenhard¹¹⁰,Amaravadi Ravi⁴¹²,Schuchter Lynn M⁴¹²,Burd Christin E¹³,Aplin Andrew E¹⁴,Xu Xiaowei⁴⁷,Villanueva Jessie¹¹⁰^ORCID

Affiliation:

1. Molecular & Cellular Oncogenesis Program The Wistar Institute Philadelphia PA USA

2. College of Computing Sciences New Jersey Institute of Technology Newark NJ USA

3. Abramson Cancer Center University of Pennsylvania Philadelphia PA USA

4. Department of Surgery Hospital of the University of Pennsylvania Philadelphia PA USA

5. Center for Personalized Diagnostics Hospital of the University of Pennsylvania University of Pennsylvania Philadelphia PA USA

6. Department of Pathology and Laboratory Medicine Hospital of the University of Pennsylvania Philadelphia PA USA

7. Department of Systems Biology The University of Texas MD Anderson Cancer Center Houston TX USA

8. Massachusetts General Hospital Cancer Center Harvard Medical School Boston MA USA

9. Department of Surgery Massachusetts General Hospital Harvard Medical School Boston MA USA

10. Melanoma Research Center The Wistar Institute Philadelphia PA USA

11. Immunology, Microenvironment and Metastasis Program The Wistar Institute Philadelphia PA USA

12. Department of Medicine Hospital of the University of Pennsylvania Philadelphia PA USA

13. Departments of Molecular Genetics and Cancer Biology and Genetics Ohio State University Columbus OH USA

14. Department of Cancer Biology and Sidney Kimmel Cancer Center Thomas Jefferson University Philadelphia PA USA

Funder

National Cancer Institute

Melanoma Research Alliance

Melanoma Research Foundation

Dr. Miriam and Sheldon G. Adelson Medical Research Foundation

National Institutes of Health

American Cancer Society

V Foundation for Cancer Research

Publisher

EMBO

Subject

Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.15252/emmm.201708446

Reference58 articles.

1. E2F1 in Melanoma Progression and Metastasis

2. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

3. Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho

4. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

5. Epigenetics of human melanoma: promises and challenges

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints;Oncogene;2024-01-19

2. TCF19 promotes cell proliferation and tumor formation in lung cancer by activating the Raf/MEK/ERK signaling pathway;2024-01-17

3. A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma;Cell;2024-01

4. BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS‐mutant melanoma cells: Insights into mode of action and resistance mechanisms;International Journal of Cancer;2023-12-11

5. Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma;Cancers;2023-11-22